Monday, August 11, 2008
P70

Development of an Efficient Epothilone B Fermentation Process

Shu-Jen Chiang, Bruce Eagan, Mark Mascari, Kenton Doctor, Siva Sakhamuri, Rene Sitnik, David Meyers, and Hsing Hou. Technical Operations, Bristol-Myers Squibb, 6000 Thompson Road, East Syracuse, NY 13057

The epothilones A and B are produced as secondary metabolites from the fermentation of a soil myxobacterium, Sorangium cellulosum. These natural products are potent cytotoxic agents that exert microtubule-stabilizing effects similar to paclitaxel and are very active against rapidly proliferating tumor cells. Modification of the original fermentation process enabled an efficient fermentation process to produce epothilone B as a major product. The purified epothilone B is chemically converted to ixabepilone, which was recently approved by FDA.

 In the original fermentation process, epothilone A is produced preferentially over epothilone B. The inclusion of XAD-16 resin was found to dramatically improve the epothilone productivity, and also to be useful in the isolation and purification of epothilones. By adding sodium propionate to the fermentation medium, the production of epothilone B is enhanced and produced preferentially over the production of epothilone A. The increase of epothilone B productivity was slow in the original propionate fed fermentation process, indicating some of the nutrient may not be sufficient to sustain the epothilone B productivity. By taking fermentation broth at different time points and spiking the broth with individual medium components, the nutrient requirements at different fermentation time points were established. By supplementing these nutrient components during fermentation, a four to five fold improvement in epothilone B productivity was achieved.